In the past, most targeted drug development efforts relied on single biomarkers, but cancer is far more complex. BostonGene’s ...

Making a discovery with the potential for innovative applications in pharmaceutical development, a West Virginia University ...

Despite significant progress in medicinal chemistry and life sciences research, drug discovery and development remain slow and expensive, taking on average approximately 15 years and US$2 billion ...

Gubra is a highly specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. In this interview, CEO Henrik Blou reflects on Gubra’s ...

Recursion Pharmaceuticals RXRX and Schrodinger SDGR are pioneering the use of artificial intelligence (AI) in drug discovery ...

Enantiomers, or molecule pairs that are mirror images of each other, make up more than half of FDA-approved drugs in use ...

The pharmaceutical industry faces big challenges in drug discovery today – rising costs, high failure rates, and increasingly complex target diseases.

A former scientist at Google's DeepMind who co-developed the AlphaFold2 protein prediction platform, Dr Simon Kohl, has launched his own venture applying artificial intelligence to drug discovery.

A new funding round led by Maven and featuring existing backer Northstar Ventures aims to scale delivery of the firm's ...

Digital twins have tremendous potential to revolutionise drug discovery and enable precision healthcare for patients. They can accurately model disease pathways, predict the efficacy of potential ...